1709: ECTHYMA GANGRENOSUM AND SEPTIC SHOCK AS PRECEDING SYMPTOMS OF ACUTE LEUKEMIA

2016 ◽  
Vol 44 (12) ◽  
pp. 502-502
Author(s):  
Georgia Androutsopoulou ◽  
Gloria Heresi ◽  
Matthew Greives ◽  
Konstantinos Boukas
2019 ◽  
Vol 49 (4) ◽  
pp. 288-289
Author(s):  
O. Passouant ◽  
M. Hentzien ◽  
M. Viguier ◽  
V. Vernet-Garnier ◽  
F. Bani-Sadr ◽  
...  

2017 ◽  
Vol 149 (8) ◽  
pp. 363
Author(s):  
Álvaro Iglesias Puzas ◽  
Ana Batalla Cebey ◽  
Ángeles Flórez Menéndez

2021 ◽  
Vol 14 (1) ◽  
pp. e237085
Author(s):  
Christopher Saling ◽  
Fionna Feller ◽  
Holenarasipur R Vikram

Herein, we report a case of a 68-year-old woman receiving ibrutinib for chronic lymphocytic leukaemia, who presented with septic shock and a progressive necrotic lesion on her nose. Surgical pathology of the nasal lesion revealed evidence of tissue necrosis, and both tissue and blood culture grew Pseudomonas aeruginosa. A diagnosis of ecthyma gangrenosum was made. Additional investigations also led to the discovery of invasive pulmonary aspergillosis. To our knowledge, this is the first case of ecthyma gangrenosum secondary to Pseudomonas sepsis and concurrent invasive pulmonary aspergillosis associated with ibrutinib use.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4622-4622
Author(s):  
Thamires Branco Da Silva ◽  
Guilherme Rossi Assis de Mendonça ◽  
Maiara Marx Luz Fiusa ◽  
Brunna Eulalio Alves ◽  
Rodolfo Monteiro Enz Hubert ◽  
...  

Abstract Introduction: Sepsis in febrile neutropenia (FN) is a life threatening condition, and a health problem of increasing proportions. Although multiple organ dysfunction syndrome (MODS) frequently precedes death in patients with sepsis, the ultimate mechanisms responsible for organ dysfunction and tissue damage in sepsis are yet to be determined. Currently, tissue damage is attributed to an exacerbated response of the immune and hemostatic systems, mediated by endothelial cells, platelets and neutrophils. Of note, recent evidence demonstrated that neutrophils, platelets and fibrin participate in this response by mediating neutrophil extracellular traps (NET) formation, and promoting the hemostatic containment of infectious foci. In animal models, down-regulation of NET formation, coagulation and platelet activation are usually associated with deficiencies in pathogen clearance. Unfortunately, activation of hemostasis and NET formation could potentially contribute to tissue damage by a process called "immunethrombosis". Although the increase of sepsis severity in patients with severe neutropenia is well described, the mechanisms of sepsis-associated tissue damage in the context of severe neutropenia/thrombocytopenia are yet to be determined. Methods: In order to investigate the mechanisms of tissue damage in the context of severe neutropenia/thrombocytopenia, we compiled clinical data from two different prospective sepsis cohorts (A, neutropenic; n=129; and B, non-neutropenic; n=30) followed at our Institution. In addition, we reviewed histopathological data from 16 autopsies of individuals with hematological malignancies and septic shock from our institution (cohort C; n=16). H&E-stained slides from liver, kidneys and lungs were systematically analyzed by one investigator, and reviewed by 2 experienced pathologists, all of them blind to the presence or absence of neutropenia and thrombocytopenia. In each organ, we characterized (as present or absent) three main organic lesions: thrombi in microvessels, microorganism colonies, and inflammatory infiltrate (mononuclear and polymorphonuclear). Inflammation was graded as weak or intense, and only considered when there was no neoplastic infiltration. Results: Median ages of patients from cohorts A and B were respectively 46.0 years (13-78), and 59.4 years (22-85); P<0.0001. In cohort A, neutrophil counts were < 100/mcl in 55.8% of patients and between 100-500/mcl in 42.6%. Platelet counts were also lower in cohort A (30,126 vs 213,933/mcl; P<0.0001). Median SOFA scores (at admission) were 4 (0-15) and 5 (0-17); P=0.3 in neutropenic and non-neutropenic patients respectively, and sepsis-related mortality was 22.5% and 10.3% in the same groups (P=0.19). Among patients with a higher SOFA score, mortality was higher in neutropenic patients (100% vs 33.3%; p=0.04). The frequencies of clinically-evident infection foci were 60% in cohort A and 100% in cohort B (P=0.0001). In contrast, positive blood cultures were present in 38% of neutropenic, but in only 3.3% of non-neutropenic patients (P<0.0001). The autopsy-based study included 10 patients with lymphoma and 6 with acute leukemia. The cause of death was septic shock in all of them, and three patients presented severe neutropenia (<500/mcl). The main histological findings are shown in table 1. The only neutropenic patient with microthrombi presented AML-M3 and leukostasis. Using H&E staining, no bacterial colonies were found in any slide. Conclusions: as expected, septic patients with severe neutropenia presented a worse outcome compared to non-neutropenic patients in our cohort. In addition, the lower frequency of clinically-defined infectious foci, coupled with a strikingly higher frequency of positive blood cultures, suggest that severe neutropenia and thrombocytopenia could impair pathogen containment and clearance. Severe neutropenia/thrombocytopenia was compatible with inflammatory infiltrates and microvascular thrombosis in lungs, although the latter was only observed in a patient with leukostasis and promyelocityc acute leukemia. Table 1. Histological findings in autopsies of neutropenic and non-neutropenic patients Microthrombi Inflammation (weak/intense) Lungs Kidney Liver Lungs Kidney Liver Neutropenic 33% 33% 0% 50%/50% 0%/0% 0%/0% Non-neutropenic 56.25% 25% 6.25% 70%/20% 34%/9% 67%/0% Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4902-4902
Author(s):  
Nidia P. Zapata ◽  
Jorge Carlos Torres ◽  
Ramiro Espinoza ◽  
Eduardo Cervera

Abstract Infectious complications are a major cause of morbidity and mortality in hematologic patients with acute leukemia. In this paper we address the mayor infectious complications, at the Leukemia Clinic (LC) in the Instituto Nacional de Cancerologia (INCan) Material and Methods. This is a retrospective, observational study, carried on at INCan. We included all patients that attended the LC and died of an infectious complication between January 2012 and December 2014, regardless of status (new case/relapsed) at diagnosis, we included patients with Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Biphenotypic Leukemia (ABL) and Acute Promyelocytic Leukemia (APML). The main objective of the study was to determine the most frequent causes of infectious complications in the treatment of acute leukemias. Results. We included 240 patients that were admitted to the LC between the study dates. 12 patients were excluded since they were later diagnosed with another hematologic malignancy rather than leukemia. 228 patients were analyzed. 132 males, 96 females, 36 years was the median age (14-85 years). 126 patients were new cases and 102 patients were treated for relapse. AML 69 patients, ALL 140 patients, ABL 9 patients, and APML 10 patients. We revised the data of all the deaths that occurred in the period of time. 100 cases were included in the study, of those, 30 that were not infectious related and were excluded. Of the 40 patients included, 41 were males and 29 females, with a mean age of 36.8 years (16-72). 44 ALL patients, 18 AML patients, 7 ABL patients and 1 APML patient. 32 patients were new cases and 38 were relapses. The media number of relapses was 1 (1-3). Septic Shock was stated as the cause of death on all electronic files, with Pneumonia as the most common cause of infection origin with 47 patients. As for determining the causal agent of the infection, we used the last positive culture 5 days prior to the death, we found a causal agent in only 47 patients; the most frequent agents involved were: Escherichia coli BLEE with 13 patients, Enterococus faecium with 6 patients, we also report 1 H1N1 and 1 H3N2 influenza infections. 14 patients did not received intensive chemotherapy prior to death, 11 were on supportive care, and 3 of them did not consent treatment. HyperCVAD was the most frequent regimen administered prior to death, with 13 patients, 7+3 followed with 11 patients. POMP in the setting of palliative regimen was also prevalent with 12 patients. 52% of the patients were in nadir of chemotherapy, with a mean of days of 19 (3-64). All patients that received intensive chemotherapy received GSFC and meropenem/vancomycin regimen once septic shock was diagnosed according to the data in the electronic file. All patients received treatment in the beginning, of the 70 patients only 19 were treated in the intensive care unit (ICU). Conclusions. We addressed the most frequent causes of infectious complications at the Acute Leukemia Clinic, as we thought, E. coli BLEE was the most frequent agent involved, perhaps diverting from reports in the literature, we have a low prevalence of gram positive cocci. Pneumonia is the most frequent site of infection, all our patients are admitted to for chemotherapy, hence all the pneumonia cases are hospital acquired. POMP is a prevalent regimen reported, since we use this regimen for palliative care we could relate mortality to relapse/refractory disease more than to toxicity itself. No maintenance regimens were reported in the results. Our study has certain limitations, no mycotic infections could be reported as the electronic file lacks reliable information. Disclosures No relevant conflicts of interest to declare.


2014 ◽  
Vol 51 (4) ◽  
pp. 598 ◽  
Author(s):  
S Koley ◽  
G Das ◽  
RK Mandal ◽  
DC Barman ◽  
S Mallick ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5280-5280
Author(s):  
Roberta Demichelis ◽  
Erick Crespo ◽  
Fernando Pérez ◽  
Ubaldo Valencia ◽  
Patricia Guzman

Abstract Primary refractory or relapsed acute myeloid or lymphoid leukemia are characterized by unsatisfactory response to current therapy and short survival. The therapeutic approach consists on salvage chemotherapy treatment followed by allogenic hematopoietic stem-cell transplantation (HSCT). FLAG (Fludarabine, Cytarabine and G-CSF) is an effective salvage therapy in this setting. The regimen is designed with intravenous (IV) Fludarabine. In a period of time there was no IV Fludarabine available in our Country, only an oral presentation. There are some bioequivalence studies of oral and IV Fludarabine, mostly in chronic lymphocytic leukemia/low grade lymphomas. Based of these studies we treated patients with FLAG with the equivalent dose of oral Fludarabine (dose 40 mg/m2 day). This is a comparative retrospective study of efficacy and toxicity of FLAG with oral and IV Fludarabine. Forty-four patients with relapsed or refractory acute leukemia were treated with FLAG between 2005 and 2013. The diagnoses were: Pre-B ALL (63.3%), AML (31.8%), APL (2.3%) and T-ALL (2.3%). The median age was 26.7 years and 63.6% were early relapses, 20.5% primary refractory and 15.9% late relapses. In 59.1% of the cases FLAG was the second line of treatment and in 40.9% it was the third or forth line. Twenty-one patients (47.7%) were treated with oral Fludarabine and 23 patients (52.3%) with IV Fludarabine. There were no differences between both groups. Results: Complete remission (CR) rate was 31.8% (33.3% for AML and 31% for ALL), 23.8% with oral Fludarabine and 39.1% with IV Fludarabine (P=0.342). Median overall survival (OS) was 8.07 months: 6.14 months with oral Fludarabine and 10.78 months with IV Fludarabine (P=0.363). There was a higher incidence of neutropenic fever with IV Fludarabine than with oral Fludarabine (100% vs. 76.2%, P= 0.019) as well as higher incidence of septic shock (34.8% vs. 0%, P=0.003) and a longer hospitalization (26.8 vs. 19.4 days, P=0.046). On univariate analysis, the factors associated with shorter overall survival were: number of lines of treatment (more than 1 previous to FLAG) (HR: 2.03, CI 95% 1.09-3.78; P=0.03) and septic shock (HR: 2.8, CI 95% 1.24-6.36; P=0.023). Factors associated with a higher survival were: CR with FLAG (HR: 0.26, CI 95% 0.12-0.58; P<0.001) and HSCT (HR: 0.15, CI 95% 0.02-1; P= 0.009). On multivariate analysis, factors that remained significant were number of lines of treatment (HR: 2.5, CI 95% 1.26-4.99; P= 0.009), septic shock (HR: 3.93, CI 95% 1.67-9.25; P=0.002) and CR with FLAG (HR: 0.18, CI 95% 0.08-0.44; P<0.001). There is a non significant tendency of better CR rates and OS with IV Fludarabine. There is a significative difference in toxicity with higher rates of neutropenic fever, septic shock and a longer hospitalization. Oral Fludarabine is effective for salvage treatment of primary refractory or relapsed acute lymphoid or myeloid leukemia. As far as we know there are no previous reports of oral fludarabine-containing FLAG in acute leukemia patients. The optimal dose needs to be determined. The prognosis is this group of patients is very poor and the responses are only transitory. Salvage chemotherapy should be used only as a bridge for HSCT. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S938-S939
Author(s):  
Yunmi Yi ◽  
Sung-Yeon Cho ◽  
Dong-Gun Lee ◽  
Jae-Ki Choi ◽  
Hyo-Jin Lee ◽  
...  

Abstract Background Fluoroquinolone prophylaxis has been widely used in high-risk neutropenic patients with hematological malignancies, which may reduce bloodstream infection (BSI) and mortality. However, concerns about antibiotic resistance also exist. The aim of this study was to assess the impact of new institutional strategy of restricting fluoroquinolone prophylaxis and saving carbapenem, applied since October 2016. Fluoroquinolone prophylaxis was adopted only in remission induction chemotherapy, and carbapenems were saved until other antibiotics prove no effectiveness Methods We retrospectively reviewed all consecutive intensive chemotherapy episodes for acute leukemia from April 2016 to March 2017 at the Catholic Hematology Hospital. In addition, antibiotics consumption was assessed by calculating defined daily doses (DDDs) per 100 bed-days. Results Among 420 admissions during the study period, 201 and 219 admissions were identified before (period 1) and after (period 2) the strategy modification. Baseline characteristics including types of leukemia, chemotherapy, severity and duration of neutropenia were not different between the two periods.Development of febrile neutropenia (83.6% vs. 84.0%, P = 0.487), BSI (46.3% vs. 52.5%, P = 0.291), and septic shock (4.0% vs. 6.4%, P = 0.268) were not significantly different. Polymicrobial BSI increased significantly (7.1% vs. 20.0%, p = 0.012) in period 2. Quinolone resistance (97.8% vs. 43.6%, P < 0.001) and extended-spectrum β-lactamase producers (50% vs. 29.1%, P = 0.032) among Enterobacteriaceae were significantly reduced. Carbapenem-resistant Enterobacteriaceae was not isolated in period 2. Vancomycin resistance among enterococci (66.7% vs. 15%, P = 0.006) decreased. Consumption of ciprofloxacin (37.2 vs. 13.8) and carbapenem (22.3 vs. 16.8) decreased, while piperacillin/tazobactam consumption increased (5.2 vs. 13.0). BSI-related death (1.0% vs. 0.9%) was not increased. Conclusion Fluoroquinolone prophylaxis restriction and carbapenem saving strategies resulted in significant reduction of resistant bacterial BSIs, without increase in febrile neutropenia, BSI, septic shock, and BSI-related death. Antibiotics stewardship program can be tried in neutropenic patients, which may improve the ultimate outcome. Disclosures All authors: No reported disclosures.


2022 ◽  
Vol 13 (1) ◽  
pp. 98-98
Author(s):  
Samia Mrabat ◽  
Hanane Baybay ◽  
Ryme Dassouly ◽  
Zakia Douhi ◽  
Sara Elloudi ◽  
...  

Ecthyma gangrenosum (EG) is a cutaneous infection most commonly associated with Pseudomonas bacteremia and usually occurring in immunocompromised patients [1]. The infection progresses sequentially from a maculopapular rash to hemorrhagic bullae, then to necrotic ulcerations with surrounding erythema [2]. Herein, we report a case of ecthyma gangrenosum in an immunologically compromised patient. A 65-year-old female was admitted to the oncohematology department for febrile pancytopenia. Blood work revealed severe thrombocytopenia at 15,000/mm³), an absolute neutrophil count of 180 cells/mm³, and anemia. A sternal bone marrow puncture found 15% of plasma cells. Four days after the admission, the patient had a painful, quickly extending lesion on the abdomen. She described erythema that progressed to pustules, then ulcerations. On general clinical evaluation, the patient was feverish at 40°C. A dermatological examination revealed the presence of a 6 cm purpuric patch on the left flank with a central necrotic eschar (Fig. 1). The diagnosis of ecthyma gangrenosum was reached and the patient was treated with ceftazidime and vancomycin. Unfortunately, having gone into septic shock, the patient died one week later.


Sign in / Sign up

Export Citation Format

Share Document